Mirae Asset Global Investments
KALV

Mirae Asset Global Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Mirae Asset Global Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,636
Closed -$53.1K – 1713
2026
Q1 		$53.1K Buy
2,636
+180
+7% +$2.9K ﹤0.01% 1287
2025
Q4 		$39.7K Buy
2,456
+510
+26% +$6.75K ﹤0.01% 1440
2025
Q3 		$23.7K Buy
1,946
+25
+1% +$345 ﹤0.01% 1474
2025
Q2 		$21.7K Buy
1,921
+281
+17% +$3.44K ﹤0.01% 1388
2025
Q1 		$19.6K Buy
1,640
+17
+1% +$174 ﹤0.01% 1388
2024
Q4 		$13.8K Buy
1,623
+65
+4% +$673 ﹤0.01% 1475
2024
Q3 		$19.2K Buy
1,558
+298
+24% +$3.75K ﹤0.01% 1440
2024
Q2 		$15.2K Sell
1,260
-9,375
-88% -$109K ﹤0.01% 1424
2024
Q1 		$78.7K Buy
10,635
+375
+4% +$5K ﹤0.01% 2395
2023
Q4 		$126K Buy
+10,260
New +$93.3K ﹤0.01% 2418
2022
Q4 		– Sell
-10,014
Closed -$145K – 2564
2022
Q3 		$145K Buy
+10,014
New +$140K ﹤0.01% 2433

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's KALV Position: Q2 2026 in Review

Mirae Asset Global Investments sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,636 shares — an estimated $53.1K sold.

Mirae Asset Global Investments first reported a position in KALV in Q3 2022 and held it in 11 quarters. The position peaked at $145K in Q3 2022. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Mirae Asset Global Investments reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,636 KalVista Pharmaceuticals shares in Q2 2026, an estimated $53.1K.
  • Mirae Asset Global Investments first reported a position in KalVista Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Mirae Asset Global Investments's KalVista Pharmaceuticals position peaked at $145K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.